PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-42.34%
Both companies show declining cash positions (-42.34% vs CRVO's -64.29%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-42.34%
Cash + STI yoy 0.5-0.75x CRVO's -64.29%. Martin Whitman would worry about lagging short-term reserves. Confirm debt coverage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-29.91%
Higher Other Current Assets Growth compared to CRVO's zero value, indicating worse performance.
-41.98%
0.75-0.9x CRVO's -53.99%. Bill Ackman would ask if competitor is building short-term resources more aggressively.
-100.00%
≥ 1.5x CRVO's -18.66%. David Dodd sees more aggressive capex. Confirm it's not overspending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Higher Other Non-Current Assets Growth compared to CRVO's zero value, indicating worse performance.
-100.00%
≥ 1.5x CRVO's -0.46%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
-42.01%
≥ 1.5x CRVO's -10.56%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
-48.73%
Above 1.5x CRVO's -1.47%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
-46.67%
Less than half of CRVO's 5.49%. David Dodd sees much smaller short-term leverage burden vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-37.33%
Less than half of CRVO's 2.43%. David Dodd sees fewer expansions in other current obligations.
-39.56%
Less than half of CRVO's 5.14%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-39.56%
Less than half of CRVO's 5.14%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-1.24%
Below half CRVO's -3.66%. Michael Burry suspects major net losses or high dividends vs. competitor.
99.72%
Higher AOCI Growth compared to CRVO's zero value, indicating worse performance.
-100.00%
Higher Other Stockholders' Equity Items Growth compared to CRVO's zero value, indicating worse performance.
-51.92%
≥ 1.5x CRVO's -7.20%. David Dodd sees stronger capital base growth than competitor.
-42.01%
≥ 1.5x CRVO's -10.56%. David Dodd sees faster overall balance sheet growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
-46.67%
Less than half of CRVO's 5.49%. David Dodd sees less overall debt expansion vs. competitor.
42.23%
Above 1.5x CRVO's 11.39%. Michael Burry sees a major gap in net debt growth. Check coverage and liquidity.